CRVS

Corvus Pharmaceuticals Inc

10.23

Oct 23 • 11:01 AM ET -0.42 (-3.94%)

Healthcare Biotechnology USA Small NASD

Peers: ACRS ALMS KYMR EVMN INCY ARQT ORKA RIGL UPB ABBV

| Held by: VTI XBI IWM VXF IWO IBB VTWO SCHA VHT IWC

Index	RUT
Market Cap	860.58M
Enterprise Value	646.08M
Income	-54.13M
Sales	0.00M
Book/sh	2.68
Cash/sh	2.56
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	37
IPO	Mar 23, 2016

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	3.82
P/C	4.00
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	16.16
Current Ratio	16.16
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-0.62
EPS next Y	-0.93
EPS next Q	-0.19
EPS this Y	-293.49%
EPS next Y	-24.31%
EPS next 5Y	-
EPS past 3/5Y	15.40% -21.44%
Sales past 3/5Y	- -
EPS Y/Y TTM	8.13%
Sales Y/Y TTM	-
EPS Q/Q	-89.11%
Sales Q/Q	-
Earnings	Aug 06 AMC
EPS/Sales Surpr.	-19.42% -

Insider Own	22.97%
Insider Trans	0.15%
Inst Own	65.81%
Inst Trans	1.38%
ROA	-32.93%
ROE	-35.43%
ROIC	-23.99%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-1.84%
SMA50	-17.42%
SMA200	-28.72%
Trades

Shs Outstand	84.12M
Shs Float	64.80M
Short Float	27.47%
Short Ratio	17.94
Short Interest	17.80M
52W High	26.95 -62.04%
52W Low	6.39 60.10%
Volatility	6.75% 6.23%
ATR (14)	0.65
RSI (14)	42.36
Beta	1.55
Rel Volume	0.87
Avg Volume	991.97K
Volume	235,041

Perf Week	7.46%
Perf Month	-13.30%
Perf Quarter	-20.82%
Perf Half Y	-36.38%
Perf YTD	32.86%
Perf Year	42.88%
Perf 3Y	781.92%
Perf 5Y	128.87%
Perf 10Y	-29.20%
Recom	1.12
Target Price	33.14
Prev Close	10.65
Price	10.23
Change %	-3.94%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-17-26	Initiated	Goldman	Buy	$40
Oct-13-25	Initiated	Barclays	Overweight	$16
Jan-02-25	Initiated	H.C. Wainwright	Buy	$11
Aug-18-23	Initiated	Oppenheimer	Outperform	$7
Dec-01-21	Resumed	Jefferies	Buy	$8
May-27-21	Initiated	Cantor Fitzgerald	Overweight	$10
Feb-10-21	Downgrade	Mizuho	Buy → Neutral	$7 → $4
Sep-12-19	Initiated	Mizuho	Buy
May-29-19	Initiated	ROTH Capital	Buy	$6
Aug-24-17	Upgrade	Credit Suisse	Underperform → Neutral
May-01-17	Downgrade	Credit Suisse	Neutral → Underperform
Apr-18-16	Initiated	Guggenheim	Buy
Apr-18-16	Initiated	Credit Suisse	Outperform

Show Previous Ratings

Sep-30-26 04:05PM	Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa (GlobeNewswire) -5.12%
Sep-03-26 08:30AM	Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-27-26 07:30AM	Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial (GlobeNewswire)
Aug-07-26 01:09AM	Corvus Pharmaceuticals Inc (CRVS) (Q2 2026) Earnings Call Highlights: Advancing Soquelitinib ... (GuruFocus.com)
Aug-06-26 04:36PM	Corvus: Q2 Earnings Snapshot (Associated Press)
04:01PM	Loading…
04:01PM	Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results (GlobeNewswire)
Jul-30-26 04:01PM	Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026 (GlobeNewswire)
Jun-09-26 07:30AM	Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China (GlobeNewswire)
May-20-26 04:01PM	Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference (GlobeNewswire) +6.00% +7.30%
May-14-26 07:00AM	Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting (GlobeNewswire) -13.79%
May-07-26 04:44PM	Corvus: Q1 Earnings Snapshot (Associated Press) -5.57% +6.58%
04:01PM	Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results (GlobeNewswire)
Apr-23-26 07:30AM	Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors (GlobeNewswire) -10.25%
Apr-21-26 07:30AM	Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting (GlobeNewswire) +10.30%
Apr-17-26 09:36AM	Apple upgraded, Qualcomm downgraded: Wall Street's top analyst calls (The Fly) +11.30%
11:07PM	Loading…
Mar-12-26 11:07PM	Corvus Pharmaceuticals Inc (CRVS) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com) -5.27%
04:08PM	Corvus: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Mar-05-26 04:01PM	Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 (GlobeNewswire) -9.98%
Feb-27-26 12:39PM	Corvus Pharmaceuticals Highlights Soquelitinib Pipeline, Eyes Phase II Atopic Dermatitis Trial in 2026 (MarketBeat)
Feb-23-26 04:01PM	Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Feb-02-26 10:39AM	Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026 (MarketBeat)
Jan-27-26 12:15PM	Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why (Zacks)
12:00PM	Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should Know (Zacks)
09:55AM	Wall Street Analysts Think Corvus (CRVS) Could Surge 25.29%: Read This Before Placing a Bet (Zacks)
05:03AM	Corvus Pharmaceuticals (CRVS) Falls on Profit-Taking After 212% Jump (Insider Monkey)
Jan-25-26 07:47PM	Corvus Pharmaceuticals (CRVS) Soars 212% on Impressive Eczema Therapy Study (Insider Monkey)
Jan-23-26 05:00PM	Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M (GlobeNewswire) -8.33%
08:11AM	Corvus Pharmaceuticals (CRVS) Hits All-Time High on Eczema Trial Results (Insider Monkey)
03:01AM	Corvus Pharmaceuticals Shares New Phase I Soquelitinib Data Showing Strong AD EASI Gains (MarketBeat)
10:53PM	Loading…
Jan-21-26 10:53PM	Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire) +15.21%
06:39AM	Corvus shares nearly triple on positive data for eczema pill (BioPharma Dive)
Jan-20-26 04:08PM	Why Small Biotech Stock Corvus Pharma Just Launched To A Nine-Year High (Investor's Business Daily) +165.96%
04:01PM	Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
02:00PM	Corvus Stock Spikes On Heels Of Strong Eczema Study Results (Benzinga)
07:00AM	Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis (GlobeNewswire)
Jan-16-26 04:01PM	Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis (GlobeNewswire) +12.75%
Jan-05-26 08:30AM	Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference (GlobeNewswire) -7.24%
Dec-08-25 10:30AM	Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial (GlobeNewswire)
Nov-04-25 04:51PM	Corvus: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-03-25 09:02AM	Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition (GlobeNewswire)
Oct-31-25 07:30AM	Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference (GlobeNewswire)
Oct-28-25 04:01PM	Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025 (GlobeNewswire)
Oct-17-25 10:00AM	Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025 (GlobeNewswire) -7.97%
Oct-02-25 04:01PM	Corvus Pharmaceuticals Appoints David Moore to Board of Directors (GlobeNewswire)
Aug-07-25 04:17PM	Corvus: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-01-25 09:00AM	BioMarin Announces Appointment of Ian T. Clark to Board of Directors (PR Newswire)
Jul-31-25 04:01PM	Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2025 Financial Results on August 7, 2025 (GlobeNewswire)
Jun-25-25 08:00AM	Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis (GlobeNewswire) -5.07%
Jun-11-25 07:00AM	Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress (GlobeNewswire) +5.88%
Jun-04-25 07:00AM	Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis (GlobeNewswire) -8.98%
May-28-25 04:01PM	Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference (GlobeNewswire)
May-09-25 08:32AM	Is Corvus Pharmaceuticals, Inc. (CRVS) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey) +32.24%
03:41AM	Corvus Pharmaceuticals Inc (CRVS) Q1 2025 Earnings Call Highlights: A Turnaround with Promising ... (GuruFocus.com)
May-08-25 04:39PM	Corvus: Q1 Earnings Snapshot (Associated Press Finance)
04:02PM	Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results (GlobeNewswire)
04:01PM	Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis (GlobeNewswire)
May-07-25 05:35PM	Corvus Pharmaceuticals Q1 2025 Earnings Preview (Seeking Alpha)
Apr-23-25 04:08PM	Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025 (GlobeNewswire) +5.71%
Apr-22-25 06:47PM	Is Corvus Pharmaceuticals, Inc. (CRVS) the Best Multibagger Penny Stock to Buy According to Billionaires? (Insider Monkey)
Apr-09-25 04:01PM	Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors (GlobeNewswire)
Mar-28-25 09:30AM	Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials (Seeking Alpha)
09:29AM	Corvus Pharmaceuticals: Now At Cruising Altitude (Seeking Alpha)
Mar-26-25 10:39AM	Q4 2024 Corvus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -14.76%
03:02AM	Corvus Pharmaceuticals Inc (CRVS) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Mar-25-25 07:58PM	Corvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call Transcript (SeekingAlpha) -7.53%
04:09PM	Corvus: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-20-25 08:00AM	Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma (GlobeNewswire)
Mar-19-25 04:01PM	Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference (GlobeNewswire) -5.76%
Mar-17-25 04:01PM	Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 (GlobeNewswire)
Mar-12-25 08:00AM	Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) (GlobeNewswire) +5.95%
Feb-04-25 08:00AM	Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire) +5.33%
Jan-13-25 07:30AM	Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis (GlobeNewswire)
Jan-07-25 04:01PM	Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-24 01:23PM	Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday? (Benzinga) -36.40%
07:30AM	Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis (GlobeNewswire)
06:45AM	Tessera gets sickle cell funding; Corvus shares slide on eczema data (BioPharma Dive)
Dec-17-24 04:01PM	Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024 (GlobeNewswire) +7.10%
Dec-04-24 04:05PM	Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity (GlobeNewswire)
Nov-14-24 10:01AM	Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis (GlobeNewswire)
Nov-13-24 02:18AM	Corvus Pharmaceuticals Inc (CRVS) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid ... (GuruFocus.com)
Nov-12-24 04:13PM	Corvus: Q3 Earnings Snapshot (Associated Press Finance) -9.10%
04:01PM	Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-09-24 01:40PM	Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer (GlobeNewswire)
Nov-05-24 04:02PM	Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024 (GlobeNewswire)
Sep-10-24 08:30AM	Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (GlobeNewswire) +13.88%
Sep-03-24 04:05PM	Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -9.82%
Aug-06-24 04:15PM	Corvus: Q2 Earnings Snapshot (Associated Press Finance) +6.38% +9.67%
04:01PM	Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-01-24 08:30AM	Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) (GlobeNewswire) +16.34%
Jul-31-24 08:30AM	Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024 (GlobeNewswire)
Jul-25-24 08:30AM	Publication of Preclinical Data in Science Signaling Demonstrated the Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Treatment of Inflammatory Diseases (GlobeNewswire) +6.45%
May-31-24 10:00AM	The 2024 Millionaire's Club: 3 Penny Stocks to Buy Now (InvestorPlace)
May-30-24 04:02PM	Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference (GlobeNewswire)
May-12-24 03:26PM	13 Penny Stocks with Insider Buying in 2024 (Insider Monkey)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Moore David Scott	Director	Jun 11 '26	Buy	11.53	21,700	250,236	21,700	Jun 15 05:12 PM
MILLER RICHARD A MD	President and CEO	May 18 '26	Buy	12.04	6,932	83,453	1,195,035	May 20 04:12 PM
Thompson Peter A.	Director	Jan 28 '26	Option Exercise	5.33	210,000	1,119,374	210,000	Jan 30 06:39 PM

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Co-FounderDr. Richard A. Miller M.D.

M.D.Dr. Peter A. Thompson FACP

Chief Financial OfficerMr. Leiv Lea

Senior Vice President of Pharmaceutical DevelopmentDr. William Benton Jones Ph.D.

Senior VP & Chief Business OfficerMr. Jeffrey S. Arcara

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRVS

Corvus Pharmaceuticals Inc

Upgrade your Finviz experience